In which Big Brained economist and cancer patient Charles Manski identifies* how distorting the incentives are in cancer care and drug development... I love stories that combine economics, economists, and health policy. *yeah, a bit of inside-baseball there by @arthurallen202.bsky.social
Lower dosages of popular cancer drugs might fight disease as well as what the label recommends, while reducing side effects and “financial toxicity” @arthurallen202.bsky.social reports ⤵️